ArticleFrontiers in endocrinology2026
Incremental prognostic value of the fibrinogen-to-albumin ratio for adverse perinatal outcomes in preeclampsia: a dual-center retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate whether the fibrinogen-to-albumin ratio (FAR) provides incremental prognostic value for identifying preeclamptic patients at high risk of adverse peripartum events, defined as a composite adverse perinatal outcome (CAPO) that serves as a surrogate for severe disease burden, and to explore its potential utility in guiding anesthesia-relevant decisions. Methods: This dual-center retrospective cohort study included 924 preeclamptic patients from two tertiary referral hospitals. Patients from center A ( Results: In the training cohort, model A achieved an AUC of 0.852 (95% confidence interval [CI] 0.818-0.887), whereas model B demonstrated significantly improved discrimination with an AUC of 0.888 (95% CI 0.859-0.917; Conclusions: FAR provides statistically significant incremental prognostic value for predicting CAPO, a composite of severe peripartum events. From an anesthesiology perspective, FAR ≥0.135 alerts to coagulopathy and systemic inflammation, supporting cautious neuraxial anesthesia, early invasive monitoring, and escalated perioperative care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.